FDA
-
-
-
-
-
-
-
PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA
-
-
-
-
-
-
-
PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025
-
-
-
-
-
-
-
PolyPid Ltd. (PYPD) PT Lowered to $14 at Citizens JMP
-
-
-
-
-
-
-
PolyPid Provides Corporate Update and Reports Third Quarter 2024 Financial Results
-
-
-
-
-
-
-
PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections
-
-
-
-
-
-
-
PolyPid Ltd. (PYPD) Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX100 for the Prevention of Surgical Site Infections i
-
-
-
-
-
-
-
PolyPid Ltd. (PYPD) Reports Publication of Phase 2 Clinical Trial Results for D-PLEX
-
322,090 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

